Patents by Inventor Tom KNUDSEN

Tom KNUDSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250177482
    Abstract: Provided herein are dosing regimens for the treatment of ocular conditions such as age-related macular degeneration (AMD). The regimens comprise administering to a subject in need thereof fusion constructs comprising a Complement Factor I (CFI) and a binding partner at specified doses and frequencies.
    Type: Application
    Filed: November 1, 2024
    Publication date: June 5, 2025
    Inventors: Grant E. BLOUSE, Natacha LE MOAN, Tom KNUDSEN
  • Publication number: 20250136965
    Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
    Type: Application
    Filed: September 9, 2024
    Publication date: May 1, 2025
    Inventors: Grant E. BLOUSE, Brajesh KUMAR, Tom KNUDSEN, Jan Kristian JENSEN, Emil OLDENBURG, Christine René SCHAR, Matthew John TRAYLOR, Eric Steven FURFINE, Jeffrey Charles WAY, Agnieszka JENDROSZEK, Arzu SANDIKCI, Jim MCGUIRE, Shyam Rajan IYER, Natacha LE MOAN
  • Patent number: 12116606
    Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: October 15, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Grant E. Blouse, Brajesh Kumar, Tom Knudsen, Jan Kristian Jensen, Emil Oldenburg, Christine René Schar, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way, Agnieszka Jendroszek, Arzu Sandikci, Jim McGuire, Shyam Rajan Iyer, Natacha Le Moan
  • Publication number: 20230038638
    Abstract: Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
    Type: Application
    Filed: June 14, 2021
    Publication date: February 9, 2023
    Inventors: Grant E. BLOUSE, Brajesh KUMAR, Tom KNUDSEN, Jan Kristian JENSEN, Emil OLDENBURG, Christine René SCHAR, Matthew John TRAYLOR, Eric Steven FURFINE, Jeffrey Charles WAY, Agnieszka JENDROSZEK, Arzu SANDIKCI, Jim MCGUIRE, Shyam Rajan IYER, Natacha LE MOAN
  • Patent number: 11266724
    Abstract: Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: March 8, 2022
    Assignee: CATALYST BIOSCIENCES, INC.
    Inventors: Grant E. Blouse, Tom Knudsen, Howard Levy
  • Publication number: 20210187083
    Abstract: Provided herein are modified FVII polypetides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 24, 2021
    Inventors: Grant E. BLOUSE, Tom KNUDSEN, Howard LEVY
  • Publication number: 20210069306
    Abstract: Provided herein are modified FVII polypeptides, and modified FVIIa polypeptides, and methods of treatment of acute and episodic bleeding with modified FactorVIIa polypeptides. To effect treatment and use, in some embodiments, the modified polypeptides are subcutaneously administered to provide on-demand treatment. In some embodiments, the on-demand treatment is provided in a multiple dosing regimen over a twenty-four hour period. The subcutaneous administration of the modified polypeptides of the disclosure exhibit increased coagulant activity, potency, bioavailablilty and prolonged duration.
    Type: Application
    Filed: August 15, 2020
    Publication date: March 11, 2021
    Inventors: Grant E. BLOUSE, Tom KNUDSEN, Howard LEVY